Concord Biotech Limited — Investor Meet, 19-11-2024: Analysts/Institutional Investor Meet/Con. Call Updates

1. **Financial Performance**: Concord Biotech's revenue for Q2FY25 was INR 310 crore, an 18% increase year-over-year (YoY) from INR 262 crore in Q2FY24. Profit After Tax (PAT) rose to INR 99 crore, reflecting an 18% YoY growth from INR 84 crore. EBITDA also showed a promising increase, reaching INR 137 crore, a 15% rise compared to the previous year. EBITDA margins were impressive at 44%. For H1FY25, total revenue was INR 526 crore, up 15% from INR 457 crore in H1FY24.

2. **Future Outlook and Growth Drivers**: Management expressed optimism about sustained growth driven by expanding into new therapeutic areas such as oncology and antifungal treatments. The upcoming injectable facility is expected to enhance product offerings and market reach by the end of FY25. The strong pipeline of products suggests a continued focus on research and development.

3. **Order Book and Operational Updates**: The API business’s revenue for Q2FY25 was INR 230 crore, with a notable 3% YoY growth, while the formulation segment surged 125% to INR 80 crore driven by increased approvals and a broader product portfolio. The company aims to maintain a balanced mix between APIs and formulations.

4. **Analyst Q&A Insights**: Analysts highlighted concerns about the comparatively muted growth in external API sales, attributed to interunit sales to formulations. Management clarified that the API segment is expected to see significant traction moving forward, targeting double-digit growth for the fiscal year. Analysts also inquired about the competition landscape, with management noting limited competition within the fermentation space, particularly in immunosuppressants and anti-infectives.

5. **Market or Regulatory Updates**: The company reported ongoing regulatory approvals from both domestic and international authorities, bolstering confidence in its product quality and reliability.

6. **Strategic Focus Areas**: Concord’s approach remains centered on enhancing formulation capabilities and expanding its production capacity, particularly with the launch of the injectable facility, while continuing to strengthen its position in fermentation-based APIs.

7. **Investor Insight**: The observed financial strength, growth potential across new segments, and strategic initiatives suggest a favorable outlook for investors, positioning the company well for continued growth despite short-term fluctuations in specific segments. Given the fundamentals and strategic direction, there is a compelling case to consider a ‘buy’ position.